# Trinomab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trinomab

- Industry: Biotechnology
- Headquarters: Zhuhai, China
- Website: www.trinomab.com
- Total disclosed funding: $178M
- Latest round: Series A (Aug 13, 2021)
- Investors on record: 11

## About

Established in 2015 and based in Zhuhai, China, Trinomab is a biopharmaceutical company engaged in the R&D of novel fully native human monoclonal antibody (mAb) drugs. The Chairman and CTO, Huaxin Liao, graduated from Shanghai Medical University. The CEO and President, Weihong Zheng, was the General Manager of Oasis Pharmaceutical Co., Ltd. In November 2022, TNM002 entered Phase III clinical trial. In April 2021, the antibody production base in Zhuhai International Health Port was completed and put into operation.In April 2023, Trinomab raised approximately CNY 200 million in strategic investment from new investors Kangjun Capital, Huajin Securities, Fresscon Capital, China Science & Merchants Capital Management, and China Medical System Holdings.

The company is developing multiple product pipelines. Those new drugs will be used for prevention of respiratory syncytial virus (RSV) infection, prevention of tetanus, herpes zoster virus, hCMV infection, arthralgia, bacterial infectious shock, and rabies prevention. Those drugs' development is based on the self-developed human monoclonal antibodies (Hitmab) platform.

## Funding rounds

- Series A, Aug 13, 2021, $108M — China International Capital Corporation, CMB International Asset Management, Sunshare Capital Management, Shenzhen Guozhong Venture Capital, Riverhead Capital, Superstring Capital Management, Guangzhou Tianhui Capital Management
- Series A, Apr 26, 2021, $70M — Wuxi Guolian Industrial Investment Private Equity Fund Management, Glory Ventures, CMS Ventures, Wuxi AppTec Group

## Investors

- Wuxi Guolian Industrial Investment Private Equity Fund Management — Series A
- Glory Ventures (https://capitalatlas.ai/funds/glory-ventures) — Series A
- CMS Ventures (https://capitalatlas.ai/funds/cms-ventures) — Series A
- Wuxi AppTec Group — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series A
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series A
- Sunshare Capital Management (https://capitalatlas.ai/funds/sunshare-capital-management) — Series A
- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series A
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series A
- Superstring Capital Management (https://capitalatlas.ai/funds/superstring-capital-management) — Series A
- Guangzhou Tianhui Capital Management — Series A